Last reviewed · How we verify
NCT00014859
Epidemiology of Surfactant Protein-B Deficiency
trial in Lung Diseases in 5,176 participants. Completed in 26 April 2024.
26 April 2024
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,176 |
| Start date | 1 June 2001 |
| Primary completion | 26 April 2024 |
| Estimated completion | 26 April 2024 |
| Sites | 1 location across United States |
Conditions studied
- Lung Diseases — all drugs for Lung Diseases →
- Respiratory Distress Syndrome, Newborn — all drugs for Respiratory Distress Syndrome, Newborn →
- Pulmonary Surfactant — all drugs for Pulmonary Surfactant →
- Lung Diseases, Interstitial — all drugs for Lung Diseases, Interstitial →
Sponsor
Washington University School of Medicine
Who can join
Under 1, any sex, with Lung Diseases or Respiratory Distress Syndrome, Newborn. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to test the hypothesis that excess, rare, functionally disruptive single nucleotide polymorphisms (SNPs) characterize genes (e.g., the surfactant protein-B gene)(SFTPB) and gene networks (e.g., the pulmonary surfactant metabolic network or other gene networks that regulate alveolar type 2 cell function) associated with increased risk of neonatal respiratory distress syndrome (RDS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00014859
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Diseases
Currently open trials in the same condition.
- NCT07356076 — The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases · recruiting
- NCT07243964 — Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation · recruiting
- NCT07270744 — Data Collection Using Eko Devices in a Clinical Setting · recruiting
- NCT07227376 — Data Collection Using Eko Digital Devices in a Clinical Setting · recruiting
- NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00014859 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 29 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00014859.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing